Insider Selling: KALA BIO, Inc. (NASDAQ:KALA) CEO Sells 5,779 Shares of Stock

KALA BIO, Inc. (NASDAQ:KALA) CEO Mark T. Iwicki sold 5,779 shares of KALA BIO stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $44,093.77. Following the transaction, the chief executive officer now directly owns 280,076 shares in the company, valued at approximately $2,136,979.88. The trade was a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

KALA BIO Stock Performance

Shares of KALA opened at $6.82 on Friday. The company has a 50-day moving average of $6.70 and a two-hundred day moving average of $6.33. The stock has a market cap of $31.44 million, a price-to-earnings ratio of -0.55 and a beta of -2.11. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15. KALA BIO, Inc. has a one year low of $4.21 and a one year high of $9.25.

KALA BIO (NASDAQ:KALA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, topping the consensus estimate of ($2.43) by $0.50. On average, equities research analysts expect that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a report on Friday, November 15th.

Institutional Trading of KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest position. SR One Capital Management LP owned 15.76% of KALA BIO as of its most recent SEC filing. Institutional investors and hedge funds own 24.61% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.